TXNDC5 and prostate carcinoma: It was reported that TXNDC5 was also found to have procarcinogenic effects in tissues of several cancers, including prostate cancer (PCa) (129), colorectal cancer (CRC) (130) (127), lung cancer (LCA) (131), non-small cell lung cancer (NSCLC) (132), ovarian cancer (OC), gastric cancer (GC) (133, 134), cervical cancer (CC) (12), esophageal squamous cell carcinoma (ESCC) (135), and hepatocellular carcinoma (HCC) (136).